|Day Low/High||33.46 / 34.98|
|52 Wk Low/High||32.61 / 71.22|
DUBLIN, Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, Nov.
-- Initial Clinical Data From Ongoing Monotherapy Dose-Escalation Stage of Phase 1 Study to be Presented --
DUBLIN, Nov. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.
-- FDA Advisory Committee to Review New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder --
-- ALKS 5461 Demonstrated Consistent Profile of Antidepressant Activity, Safety and Tolerability in Two Phase 3 Studies --
- Competitive Grant Program Awards $1 Million to 14 Organizations for the Development or Expansion of Programs Designed to Serve Those Affected by Mental Health or Substance Use Disorders -
-- Third Quarter Revenues Increased to $248.7 Million, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales --
DUBLIN, Oct. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando, Oct.
DUBLIN, Oct. 16, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.
-- Ongoing Phase 1 Study Expanded to Assess Safety and Anti-Tumor Activity of ALKS 4230 With Pembrolizumab in Patients With Advanced Solid Tumors --
-- ALKERMES Inspiration Grants® Program Will Award Up to $1 Million for the Development or Expansion of Innovative Programs --
DUBLIN, Aug. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, Aug.
-- Second Quarter Revenues Increase to $304.6 Million, Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales --
DUBLIN, July 19, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.
-- Novel Regimen Enables Physicians to Fully Dose Up to Two Months of ARISTADA Treatment on Day One --
DUBLIN, June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13,...
-- Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile --
AAL, UBS, CYOU, LOGM and ALKS were all recently downgraded by TheStreet's Quant Ratings service.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ENVA, ERIC, GM, MHH, PJC, SONA, SVVC Downgrades: ALKS, APOG, IDT, MJCO, TYPE Initiations: CKPT Read on to get TheStreet Quant Ratings' detailed report:
Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.
Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.
Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.
While more than half the states in the U.S. have passed time limits on opioid prescription as a way to battle the epidemic, the AMA says that should be left up to the doctor and patient.
Levi & Korsinsky announces it has commenced an investigation of Alkermes plc ("Alkermes" or "the Company") (NASDAQGS:ALKS) concerning possible violations of federal securities laws.
Stocks finish down sharply on Monday, the first trading day of the second quarter, after China's Ministry of Finance announces new tariffs of up to 25% on certain U.S. products.
Alkermes says the rejection of antidepressant drug ALKS 5461 is a head-scratcher, and it's calling for a prompt meeting with the regulator to get to the bottom of the decision.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.